A5033658596- Influenza Virus Research Studies
- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Bacterial Infections and Vaccines
- Herpesvirus Infections and Treatments
- COVID-19 Clinical Research Studies
- Animal Disease Management and Epidemiology
- Viral gastroenteritis research and epidemiology
- Long-Term Effects of COVID-19
- Asthma and respiratory diseases
- Virology and Viral Diseases
- Respiratory and Cough-Related Research
- COVID-19 epidemiological studies
- Acne and Rosacea Treatments and Effects
- Data-Driven Disease Surveillance
- Viral Infections and Outbreaks Research
- Immune Response and Inflammation
- Animal Virus Infections Studies
- Viral Infections and Immunology Research
- SARS-CoV-2 detection and testing
- Infectious Encephalopathies and Encephalitis
- Healthcare Systems and Technology
- Allergic Rhinitis and Sensitization
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
2016-2025
Organización Nacional de Trasplantes
2023
TIE Kinetix (Germany)
2023
Hospital Universitario 12 De Octubre
2023
Fundación Hospital Provincial de Castellón
2009-2021
Centro de Salud Casa del Barco
2003-2015
Spanish Society of Family and Community Medicine
2007-2014
Universitat de Miguel Hernández d'Elx
2014
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2012-2013
Agència de Salut Pública de Catalunya
2009
In previous phase 1-2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant system (called HZ/su) had clinically acceptable safety profile elicited robust immune response.We conducted randomized, placebo-controlled, 3 study in 18 countries to evaluate efficacy of HZ/su adults (≥50 years age), stratified according age group (50 59, 60 69, ≥70 years). Participants received two intramuscular doses or placebo 2 months...
A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and AS01B adjuvant system was associated with a risk 97.2% lower than placebo. second performed concurrently at same sites examined safety efficacy HZ/su in 70 (ZOE-70).This randomized, placebo-controlled, phase 3 conducted 18 countries involved older. Participants received two doses placebo (assigned 1:1 ratio)...
The impact of RSV in older adults is under-recognized, and the limited existing studies on incidence hospitalizations show great variability. This study aims to estimate seasonal rates (IRs) among aged 60 (≥60) evaluate how different case definitions influence these estimates. A prospective, multicentre observational with active monitoring conducted over 10 seasons (2010/2011 2019/2020) 4-10 hospitals (depending season) that covered 21-46% region's total population (around 5 million people)....
There is a lack of European epidemiologic population-based studies on bronchiolitis and respiratory syncytial virus (RSV) including both hospitalizations primary care attendance.A retrospective cohort all children born between 2009 2012 was followed from birth to 2 years age using population health databases. We searched for global (International Classification Diseases, 9th revision, Clinical Modification codes 466.1, 466.11 466.19) RSV (code code 466.19 with positive test) in the first...
Concerns have been raised about intraseasonal waning of the protection conferred by influenza vaccination. During four seasons, we consecutively recruited individuals aged 18 years or older who had received seasonal vaccine and were subsequently admitted to hospital for infection, as assessed reverse transcription polymerase chain reaction. We estimated adjusted odds ratio (aOR) infection date vaccination, defined tertiles, early, intermediate late used a test-negative approach with early...
Background The Global Influenza Hospital Surveillance Network was established in 2012 to obtain valid epidemiologic data on hospital admissions with influenza-like illness. Here we describe the epidemiology of influenza within Northern Hemisphere sites during 2013/2014 season, identify risk factors for severe outcomes and complications, assess impact different viruses clinically relevant at-risk populations. Methods Eligible consecutive were screened inclusion at 19 hospitals Russia, Turkey,...
Abstract Background Data on the epidemiology and costs related to herpes zoster (HZ) postherpetic neuralgia (PHN) in Spain are scarce; therefore, studies needed evaluate epidemiological economic impact of HZ its most common complication, PHN. The present study aimed estimate clinical burden PHN Valencia (Spain). Methods We prospectively analyzed their attributable patients from 25 general practices Autonomous Community serving 36,030 persons aged > 14 years. All with a diagnosis who...
Epidemiologic data of Herpes Zoster (HZ) disease in Spain are scarce. The objective this study was to assess the epidemiology HZ Valencian Community (Spain), using outpatient and hospital electronic health databases.Data from 2007 2010 collected computerized databases a population around 5 million inhabitants. Diagnoses were recorded by physicians International Classification Diseases, 9th Revision, Clinical Modification (ICD-9-CM). A sample medical records under different criteria reviewed...
Influenza is a global public health problem. However, severe influenza only recently has been addressed in routine surveillance. The Global Hospital Surveillance Network (GIHSN) was established to study the epidemiology of consecutive seasons different countries. Our objective describe GIHSN approach and methods. uses prospective active surveillance identify admissions permanent residents well-defined geographic areas sites around world. A core common protocol followed. After consent, data...
The Global Influenza Hospital Surveillance Network (GIHSN) has established a prospective, active surveillance, hospital-based epidemiological study to collect and virological data for the Northern Southern Hemispheres over several consecutive seasons. It focuses exclusively on severe cases of influenza requiring hospitalization. A standard protocol is shared between sites allowing comparison pooling results. During 2014-2015 season, GIHSN included seven coordinating from six countries (St....
The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Vaccine Effectiveness (IVE). This is a prospective, active surveillance hospital-based epidemiological study collect data in GIHSN. In 2016–2017 season, 15 sites 14 countries participated GIHSN, although analyses could not be performed 2 sites. A common core protocol was used order make results comparable. Here we present GIHSN season. RT-PCR test all patients that...
In October 2020, we conducted a population-based prospective cohort study to determine post-COVID-19 complications, recovery, return usual health, and associated risk factors in 536 cases of COVID-19 outbreak Borriana (Spain) by administering an epidemiological questionnaire via phone interviews. A total 484 patients participated (90.3%), age mean 37.2 ± 17.1 years, 301 females (62.2%). Mild illness was the most common manifestation. After six months, 160 (33.1%) suffered at least one...
To estimate the effectiveness of influenza vaccine in preventing hospital admission for pneumonia non-institutionalised elderly people.This was a case-control study.All three public hospitals Castellón area Spain.Cases were people aged 65 or more not living an institution who admitted to between November 15, 1994 and March 31, 1995. Each case matched with two sex control subjects years older same week acute abdominal surgical conditions trauma. The sampling incident cases consecutive. Eighty...
ABSTRACT An experimental bivalent meningococcal outer membrane vesicle (OMV) vaccine (B:4:P1.19,15 and B:4:P1.7-2,4) has been developed to provide wide coverage particularly of the circulating strains in Europe. A randomized, controlled phase II study (study identification number, 710158/002; ClinicalTrials.gov identifier NCT00137917) evaluate immunogenicity safety three doses OMV when given healthy 12- 18-year-olds on a 0-2-4 month ( n = 162) or 0-1-6 schedule 159). control group received...
Aldaz Herce P, Alvarez Pasquin MJ, Batalla Martinez C, Comin Bertran E, Gomez Marco JJ, Martin S, et al. PAPPS actualizacion 2012: Prevencion de las enfermedades infecciosas. Barcelona: SemFYC; 2012. Disponible en: http://www.papps.org/upload/file/Grupo_Expertos_ PAPPS_4_2.pdf Pericas Bosch J, Rufi no Gonzalez 2009: 2009. http://www.papps.org/suplemento_ap_09.php Mayer MA, Vacunacion en personal sanitario y medidas basicas prevencion infecciosas el medio laboral. Sociedad Espanola Medicina...
The Global Influenza Hospital Surveillance Network (GIHSN) was developed to improve understanding of severe influenza infection, as represented by hospitalized cases. GIHSN is composed coordinating sites, mainly affiliated with health authorities, each which supervises and compiles data from one seven hospitals. This report describes the distribution viruses A(H1N1), A(H3N2), B/Victoria, B/Yamagata resulting in hospitalization during 2012–2013, network's first year. In included 21 hospitals...
While influenza vaccines aim to decrease the incidence of severe among high-risk groups, evidence vaccine effectiveness (IVE) target population is sparse. We conducted a multicentre test-negative case-control study estimate IVE against hospitalised laboratory-confirmed in 18 hospitals France, Italy, Lithuania and Navarre Valencia regions Spain. All patients aged ≥18 years, belonging presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by...